CCNB1

Summary

CCNB1 (cyclin B1, HGNC:1579) is a protein-coding gene on chromosome 5q13.2, encoding G2/mitotic-specific cyclin-B1 (P14635). Essential for the control of the cell cycle at the G2/M (mitosis) transition. It is a selective cancer dependency (DepMap: 74.0% of cell lines).

The protein encoded by this gene is a regulatory protein involved in mitosis. The gene product complexes with p34(cdc2) to form the maturation-promoting factor (MPF). The encoded protein is necessary for proper control of the G2/M transition phase of the cell cycle.

Source: NCBI Gene 891 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 66 total
• Druggable target: yes — 34 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 74.0% of screened cell lines
• MANE Select transcript: NM_031966

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1579
Approved symbol	CCNB1
Name	cyclin B1
Location	5q13.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000134057
Ensembl biotype	protein_coding
OMIM	123836
Entrez	891

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 24 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000256442, ENST00000503507, ENST00000505500, ENST00000506572, ENST00000507798, ENST00000508407, ENST00000513102, ENST00000870642, ENST00000924407, ENST00000924408, ENST00000924409, ENST00000924410, ENST00000924411, ENST00000924412, ENST00000924413, ENST00000924414, ENST00000924415, ENST00000924416, ENST00000924417, ENST00000924418, ENST00000924419, ENST00000924420, ENST00000924421, ENST00000924422, ENST00000924423, ENST00000960692

RefSeq mRNA: 3 — MANE Select: NM_031966 NM_001354844, NM_001354845, NM_031966

CCDS: CCDS3997

Canonical transcript exons

ENST00000256442 — 9 exons

Exon	Start	End
ENSE00000972025	69174251	69174409
ENSE00000972026	69174877	69175113
ENSE00000972027	69175397	69175537
ENSE00000972028	69177239	69177349
ENSE00001821671	69167150	69167283
ENSE00001938963	69177524	69178245
ENSE00003557310	69168173	69168343
ENSE00003614392	69167908	69168078
ENSE00003639776	69171270	69171452

Expression profiles

Bgee: expression breadth ubiquitous, 224 present calls, max score 99.83.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 82.8396 / max 1085.8300, expressed in 1759 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
56833	80.8225	1758
56834	2.0171	863

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	99.83	gold quality
oocyte	CL:0000023	99.76	gold quality
ventricular zone	UBERON:0003053	99.26	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	97.47	gold quality
ganglionic eminence	UBERON:0004023	97.03	gold quality
endometrium epithelium	UBERON:0004811	96.77	gold quality
embryo	UBERON:0000922	96.70	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	95.59	gold quality
mucosa of transverse colon	UBERON:0004991	93.88	gold quality
stromal cell of endometrium	CL:0002255	93.82	gold quality
lower esophagus mucosa	UBERON:0035834	92.69	gold quality
left testis	UBERON:0004533	92.05	gold quality
esophagus mucosa	UBERON:0002469	91.81	gold quality
right testis	UBERON:0004534	91.73	gold quality
testis	UBERON:0000473	91.36	gold quality
esophagus squamous epithelium	UBERON:0006920	91.12	gold quality
rectum	UBERON:0001052	90.96	gold quality
sperm	CL:0000019	90.89	gold quality
trabecular bone tissue	UBERON:0002483	90.66	gold quality
bone marrow	UBERON:0002371	90.27	gold quality
vermiform appendix	UBERON:0001154	90.25	gold quality
bone element	UBERON:0001474	89.50	gold quality
adrenal tissue	UBERON:0018303	89.48	gold quality
epithelium of esophagus	UBERON:0001976	88.50	gold quality
male germ cell	CL:0000015	88.44	gold quality
gingival epithelium	UBERON:0001949	88.40	gold quality
oral cavity	UBERON:0000167	88.01	gold quality
bone marrow cell	CL:0002092	87.16	gold quality
gingiva	UBERON:0001828	86.16	gold quality
squamous epithelium	UBERON:0006914	85.94	gold quality

Single-cell (SCXA)

Detected in 21 experiment(s), a significant marker in 15.

Experiment	Marker?	Max mean expression
E-MTAB-10485	yes	1406.86
E-GEOD-99795	yes	1300.76
E-MTAB-7249	yes	1206.46
E-MTAB-11121	yes	1166.78
E-MTAB-7052	yes	1032.55
E-MTAB-8894	yes	1004.14
E-CURD-79	yes	941.20
E-MTAB-6505	yes	684.64
E-MTAB-10290	yes	540.96
E-HCAD-10	yes	507.72
E-HCAD-13	yes	453.95
E-CURD-114	yes	319.14
E-GEOD-100618	yes	257.59
E-GEOD-125970	yes	228.00
E-MTAB-6911	no	1920.57

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AGO1, AR, BRCA1, CEBPA, CREB1, DROSHA, E2F1, E2F3, E2F4, ERG, ESR2, FOXM1, FOXO1, GPER1, HLX, IRF1, IRF4, KLF4, KLF5, MAX, MXI1, MYB, MYBL2, MYC, MYOD1, NCOR2, NFKB1, NFKB, NKX2-1, OLIG2, PPARA, PTTG1, RBCK1, RELA, RPRD1B, SP1, SSRP1, STOX1, TBP, TFAP2A

miRNA regulators (miRDB)

57 targeting CCNB1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 74.0% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• Up-regulation of CCNB1 is responsible, at least in part, for radioresistance after fractionated irradiation. (PMID:11260656)
• expression is related to apoptosis in thymus (PMID:11642719)
• Cyclin b1 promoter activity and functional cdk1 complex formation in G1 phase of human breast cancer cells (PMID:11779217)
• cyclin b1 is overexpressed in laryngeal squamous cell carcinoma (PMID:11809526)
• Overexpression of B-type cyclins alters chromosomal segregation (PMID:11960377)
• The human cyclin Bl gene is cell cycle regulated with maximal activity during G(2)/M. We examined the role of histone deacetylation in cyclin Bl regulation using the histone deacetylase inhibitor trichostatin A (TSA). (PMID:12054478)
• Overexpression of cyclin B1 is associated with esophageal disease progression (PMID:12115375)
• H-ras participates in pathways that regulate cyclin B1 expression and therefore controls the G2/M checkpoint in a p53-independent manner. (PMID:12379461)
• Nuclear accumulation is necessary for cyclin B1-dependent apoptosis. This is consistent with the idea that localization of cyclin B1 is among the factors determining the cellular decision to undergo apoptosis in response to DNA damage. (PMID:12424202)
• regulation of subcellular localization by cooperative phosphorylation, including activity of polo-like kinase 1 (PMID:12447691)
• reduction of nuclear level by induction of GADD45 (PMID:12483522)
• The limitation of detecting cyclin B1 is due to its unscheduled expression, rending cyclin B1 being detected at different time-spots in the G(1) phase. (PMID:12515609)
• Cyclin B1 transcription is enhanced by the p300 coactivator and regulated during the cell cycle by a cell cycle genes homology region-dependent repression mechanism. (PMID:12586340)
• increases significantly during colorectal carcinogenesis and during later metastasis to lymph nodes (PMID:12684677)
• in mammalian cells, the majority of cyclin B1 must be destroyed before the cell can enter anaphase (PMID:12865421)
• data suggest the maintenance of Cdk1/cyclin B1 activity in HCMV-infected cells can be explained by 3 mechanisms: accumulation of cyclin B1, inactivation of negative regulatory pathways for Cdk1, accumulation of positive factors that promote Cdk1 activity (PMID:14645578)
• Expression of Cyclin B1 correlated with differentiation and vascular invasion in NSCLC; Cyclin B1 overexpression associated with higher mean values for Ki-67 proliferative index and proliferating cell nuclear antigen labeling index and poorer prognosis. (PMID:14760118)
• exposure to nonrepairable DNA damage leads to nuclear accumulation of inactive cyclin B1-Cdk1 complexes (PMID:15181148)
• role in regulating Fas ligand transcription (PMID:15215233)
• wild-type p53 mediates transcriptional repression of cyclin B1 through the Sp1 transcription factor (PMID:15710382)
• results show that human papillomavirus type 16 E1 E4 does not inhibit the kinase activity of the Cdk1/cyclin B1 complex; instead, 16E1 E4 uses a novel mechanism in which it sequesters Cdk1/cyclin B1 onto the cytokeratin network (PMID:15767402)
• results strongly indicate that in response to genotoxic stress, Cdk5 activator-binding protein C53(C53) serves as an important regulatory component of DNA damage checkpoint through modulating cyclin dependent kinase 1-cyclin B1 function (PMID:15790566)
• Altered expression is associated with therapy failure and death in patients with multiple types of cancer. (PMID:15931389)
• in nasopharyngeal carcinoma cells, SarCNU-induced apoptosis is p53-dependent while SarCNU-induced G2/M arrest is mediated by the cyclin B1-cdc-2 complex (PMID:16142332)
• results indicated that chronic Pim-1 kinase overexpression dysregulates cyclin B1 protein expression, which contributes to the development of polyploidy by delaying cytokinesis (PMID:16221667)
• Cdc2/cyclin B1 interacts with and modulates inositol 1,4,5-trisphosphate receptor (type 1) functions. (PMID:16237118)
• Study demonstrates the independent prognostic value of cyclin B1 in diffuse large B-cell lymphoma. (PMID:16273239)
• Cyclin G1 enhanced radiation sensitivity by overriding radiation-induced G2 arrest through transcriptional upregulation of cyclin B1. (PMID:16322753)
• Increased intratumoral cyclin B1 positivity and aberrant localization of signals within the cytoplasm of tumor cells is positively correlated with tendency towards tumor progression: significant role of cyclin B1 in development and pathogenesis of RCC (PMID:16557593)
• Up-regulation of cyclin B1 expression occurred in cervical cancer and may play an important role in cervical carcinogenesis. (PMID:16614707)
• hCdc14A is differentially expressed in human cancer cells and can interact with both p53 and the Cdk1/cyclin B complex; it may play a role in carcinogenesis (PMID:16784539)
• Cdk1-mediated phosphorylation of S439 stabilizes mature SREBP1 during mitosis, thereby preserving a critical pool of active transcription factors to support lipid synthesis. (PMID:16880739)
• Mip/LIN-9 is required for the expression of B-Myb, and both proteins collaborate in the control of the cell cycle progression via the regulation of S phase and cyclin A, cyclin B, and CDK1 (PMID:17098733)
• Cyclin B1 overexpression was associated with occult cervical lymph node metastases in tongue carcinoma (PMID:17167975)
• ATM regulates G(2)/M checkpoint recovery through inhibitory phosphorylations of Artemis that occur soon after DNA damage, thus setting a molecular switch that, hours later upon completion of DNA repair, allows activation of the Cdk1-cyclin B complex. (PMID:17242184)
• c-Myb protein plays a previously unappreciated role in the G(2)/M cell cycle transition of normal and malignant human hematopoietic cells (PMID:17242210)
• During both meiotic and mitotic exit in Xenopus eggs, recombinant human cyclin B1-associated cdk1 underwent transient inhibitory phosphorylation at tyr-15. Recominant cyclin B1-cdk1 activity fell more rapidly than the cyclin B1 content. (PMID:17327911)
• Results suggest that an onocogenic role of overexpressed cyclin B1 is mainly mediated in nuclei of breast carcinoma cells, and the nuclear translocation is regulated by polo-like kinase 1 and 14-3-3sigma. (PMID:17359284)
• data strongly argue against mutational events of CDK1, cyclinB1 and cyclinA2 to play a role in gangliogliomas or focal cortical dysplasia (PMID:17359356)
• p38 signaling pathway triggering cyclin B1 proteolysis after arsenite exposure may play an important role in connecting G(2) arrest with apoptosis or genome instability. (PMID:17373649)

Cross-species orthologs

15 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccnb1	ENSDARG00000051923
mus_musculus	Ccnb1	ENSMUSG00000041431
rattus_norvegicus	Ccnb1	ENSRNOG00000058539
drosophila_melanogaster	CycA	FBGN0000404
drosophila_melanogaster	CycB	FBGN0000405
drosophila_melanogaster	CycD	FBGN0010315
drosophila_melanogaster	CycE	FBGN0010382
caenorhabditis_elegans		WBGENE00000863
caenorhabditis_elegans		WBGENE00000864
caenorhabditis_elegans		WBGENE00000865
caenorhabditis_elegans		WBGENE00000866
caenorhabditis_elegans	cyb-2.2	WBGENE00000867
caenorhabditis_elegans		WBGENE00000870
caenorhabditis_elegans	cye-1	WBGENE00000871
caenorhabditis_elegans		WBGENE00017259

Paralogs (18): CCNE1 (ENSG00000105173), CCNP (ENSG00000105219), CCNJ (ENSG00000107443), CCND1 (ENSG00000110092), CCND3 (ENSG00000112576), CCNG1 (ENSG00000113328), CCNI (ENSG00000118816), CCND2 (ENSG00000118971), CCNA1 (ENSG00000133101), CCNJL (ENSG00000135083), CCNG2 (ENSG00000138764), CCNA2 (ENSG00000145386), CCNB3 (ENSG00000147082), CCNO (ENSG00000152669), CCNB2 (ENSG00000157456), CCNF (ENSG00000162063), CCNE2 (ENSG00000175305), CCNI2 (ENSG00000205089)

Protein

Protein identifiers

G2/mitotic-specific cyclin-B1 — P14635 (reviewed: P14635)

All UniProt accessions (5): P14635, D6RHI0, E9PC90, H0Y9U8, H0YA62

UniProt curated annotations — full annotation on UniProt →

Function. Essential for the control of the cell cycle at the G2/M (mitosis) transition.

Subunit / interactions. Interacts with the CDC2 protein kinase to form a serine/threonine kinase holoenzyme complex also known as maturation promoting factor (MPF). The cyclin subunit imparts substrate specificity to the complex. Binds HEI10. Interacts with catalytically active RALBP1 and CDC2 during mitosis to form an endocytotic complex during interphase. Interacts with CCNF; interaction is required for nuclear localization. Interacts with CDK5RAP3. Interacts with RFPL4A and UBE2A. Interacts with INCA1.

Subcellular location. Cytoplasm. Nucleus. Cytoskeleton. Microtubule organizing center. Centrosome.

Post-translational modifications. Ubiquitinated by the SCF(NIPA) complex during interphase, leading to its destruction. Deubiquitinated by USP22 during G2/M phase. Phosphorylated by PLK1 at Ser-133 on centrosomes during prophase: phosphorylation by PLK1 does not cause nuclear import. Phosphorylation at Ser-147 was also reported to be mediated by PLK1 but Ser-133 seems to be the primary phosphorylation site.

Similarity. Belongs to the cyclin family. Cyclin AB subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P14635-1	1	yes
P14635-2	2

RefSeq proteins (3): NP_001341773, NP_001341774, NP_114172* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004367	Cyclin_C-dom	Domain
IPR006671	Cyclin_N	Domain
IPR013763	Cyclin-like_dom	Domain
IPR036915	Cyclin-like_sf	Homologous_superfamily
IPR039361	Cyclin	Family
IPR046965	Cyclin_A/B-like	Family
IPR048026	CCNB1_first_cyclin-box	Domain
IPR048258	Cyclins_cyclin-box	Conserved_site

Pfam: PF00134, PF02984

UniProt features (41 total): helix 20, modified residue 6, region of interest 4, turn 3, mutagenesis site 2, sequence conflict 2, strand 2, chain 1, splice variant 1

Structure

Experimental structures (PDB)

14 structures.

PDB	Method	Resolution (Å)
6GU2	X-RAY DIFFRACTION	2
5LQF	X-RAY DIFFRACTION	2.06
4Y72	X-RAY DIFFRACTION	2.3
5HQ0	X-RAY DIFFRACTION	2.3
9FH9	ELECTRON MICROSCOPY	2.5
6GU3	X-RAY DIFFRACTION	2.65
4YC3	X-RAY DIFFRACTION	2.7
6GU4	X-RAY DIFFRACTION	2.73
2B9R	X-RAY DIFFRACTION	2.9
2JGZ	X-RAY DIFFRACTION	2.9
9SKQ	ELECTRON MICROSCOPY	3.4
8TAU	ELECTRON MICROSCOPY	3.5
7NJ0	ELECTRON MICROSCOPY	3.6
8TAR	ELECTRON MICROSCOPY	4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P14635-F1	77.58	0.61

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 321, 73, 126, 128, 133, 147

Mutagenesis-validated functional residues (2):

Position	Phenotype
133	strongly impairs phosphorylation by plk1.
147	does not affect phosphorylation by plk1.

Function

Pathways and Gene Ontology

Reactome pathways

57 pathways

ID	Pathway
R-HSA-113507	E2F-enabled inhibition of pre-replication complex formation
R-HSA-156711	Polo-like kinase mediated events
R-HSA-162658	Golgi Cisternae Pericentriolar Stack Reorganization
R-HSA-174048	APC/C:Cdc20 mediated degradation of Cyclin B
R-HSA-176408	Regulation of APC/C activators between G1/S and early anaphase
R-HSA-176412	Phosphorylation of the APC/C
R-HSA-176417	Phosphorylation of Emi1
R-HSA-2299718	Condensation of Prophase Chromosomes
R-HSA-2465910	MASTL Facilitates Mitotic Progression
R-HSA-2500257	Resolution of Sister Chromatid Cohesion
R-HSA-2514853	Condensation of Prometaphase Chromosomes
R-HSA-2565942	Regulation of PLK1 Activity at G2/M Transition
R-HSA-2980767	Activation of NIMA Kinases NEK9, NEK6, NEK7
R-HSA-2995383	Initiation of Nuclear Envelope (NE) Reformation
R-HSA-3301854	Nuclear Pore Complex (NPC) Disassembly
R-HSA-4419969	Depolymerization of the Nuclear Lamina
R-HSA-6804114	TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
R-HSA-68875	Mitotic Prophase
R-HSA-69273	Cyclin A/B1/B2 associated events during G2/M transition
R-HSA-69478	G2/M DNA replication checkpoint
R-HSA-75035	Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
R-HSA-8852276	The role of GTSE1 in G2/M progression after G2 checkpoint
R-HSA-8878166	Transcriptional regulation by RUNX2
R-HSA-9725371	Nuclear events stimulated by ALK signaling in cancer
R-HSA-9825892	Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
R-HSA-113510	E2F mediated regulation of DNA replication
R-HSA-1266738	Developmental Biology
R-HSA-1640170	Cell Cycle
R-HSA-1643685	Disease
R-HSA-174143	APC/C-mediated degradation of cell cycle proteins

MSigDB gene sets: 576 (showing top): GOBP_CHROMOSOME_ORGANIZATION, WU_APOPTOSIS_BY_CDKN1A_VIA_TP53, MODULE_52, GOBP_ATTACHMENT_OF_SPINDLE_MICROTUBULES_TO_KINETOCHORE, GOBP_REGULATION_OF_CELL_CYCLE_CHECKPOINT, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, HORIUCHI_WTAP_TARGETS_DN, MODULE_451, GOBP_MUSCLE_TISSUE_DEVELOPMENT, REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_CYCLIN_B, SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_UP, HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_DN, REACTOME_PHOSPHORYLATION_OF_THE_APC_C

GO Biological Process (31): G1/S transition of mitotic cell cycle (GO:0000082), G2/M transition of mitotic cell cycle (GO:0000086), oocyte maturation (GO:0001556), in utero embryonic development (GO:0001701), mitotic spindle organization (GO:0007052), mitotic metaphase chromosome alignment (GO:0007080), spermatogenesis (GO:0007283), response to xenobiotic stimulus (GO:0009410), response to mechanical stimulus (GO:0009612), negative regulation of gene expression (GO:0010629), positive regulation of G2/M transition of mitotic cell cycle (GO:0010971), positive regulation of mRNA 3’-end processing (GO:0031442), tissue regeneration (GO:0042246), positive regulation of mitotic cell cycle (GO:0045931), response to DDT (GO:0046680), positive regulation of fibroblast proliferation (GO:0048146), digestive tract development (GO:0048565), cell division (GO:0051301), positive regulation of attachment of spindle microtubules to kinetochore (GO:0051987), ventricular cardiac muscle cell development (GO:0055015), positive regulation of cardiac muscle cell proliferation (GO:0060045), regulation of chromosome condensation (GO:0060623), protein-containing complex assembly (GO:0065003), cellular response to iron(III) ion (GO:0071283), cellular response to fatty acid (GO:0071398), cellular response to hypoxia (GO:0071456), regulation of mitotic cell cycle spindle assembly checkpoint (GO:0090266), positive regulation of mitochondrial ATP synthesis coupled electron transport (GO:1905448), response to toxic substance (GO:0009636), mitotic cell cycle phase transition (GO:0044772), positive regulation of cell cycle (GO:0045787)

GO Molecular Function (6): patched binding (GO:0005113), cyclin-dependent protein serine/threonine kinase regulator activity (GO:0016538), protein kinase binding (GO:0019901), ubiquitin-like protein ligase binding (GO:0044389), cyclin-dependent protein serine/threonine kinase activator activity (GO:0061575), protein binding (GO:0005515)

GO Cellular Component (12): spindle pole (GO:0000922), outer kinetochore (GO:0000940), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), mitochondrial matrix (GO:0005759), centrosome (GO:0005813), microtubule organizing center (GO:0005815), cytosol (GO:0005829), membrane (GO:0016020), cyclin B1-CDK1 complex (GO:0097125), cytoskeleton (GO:0005856)

Reactome top-level categories

Rollup of top-13 pathways:

Category	Pathways
G2/M Transition	3
Mitotic Prophase	3
Nuclear Envelope Breakdown	3
Mitotic Prometaphase	2
E2F mediated regulation of DNA replication	1
APC/C:Cdc20 mediated degradation of mitotic proteins	1
APC/C-mediated degradation of cell cycle proteins	1
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins	1
Regulation of APC/C activators between G1/S and early anaphase	1
Nuclear Envelope (NE) Reassembly	1
TP53 Regulates Transcription of Cell Cycle Genes	1
M Phase	1
G2/M Checkpoints	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	6
mitotic cell cycle	5
mitotic cell cycle phase transition	2
developmental process involved in reproduction	2
cyclin-dependent protein serine/threonine kinase activity	2
cell cycle G1/S phase transition	1
cell cycle G2/M phase transition	1
cell maturation	1
oocyte development	1
chordate embryonic development	1
spindle organization	1
microtubule cytoskeleton organization involved in mitosis	1
mitotic sister chromatid segregation	1
metaphase chromosome alignment	1
mitotic cell cycle process	1
male gamete generation	1
response to chemical	1
response to external stimulus	1
response to abiotic stimulus	1
gene expression	1
regulation of gene expression	1
negative regulation of macromolecule biosynthetic process	1
G2/M transition of mitotic cell cycle	1
regulation of G2/M transition of mitotic cell cycle	1
positive regulation of mitotic cell cycle phase transition	1
positive regulation of cell cycle G2/M phase transition	1
mRNA 3’-end processing	1
regulation of mRNA 3’-end processing	1
positive regulation of mRNA processing	1
regeneration	1
developmental growth	1
regulation of mitotic cell cycle	1
positive regulation of cell cycle	1
response to insecticide	1
positive regulation of cell population proliferation	1
fibroblast proliferation	1
regulation of fibroblast proliferation	1
tube development	1
digestive system development	1
cellular process	1

Protein interactions and networks

STRING

5990 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCNB1	CDK1	P06493	999
CCNB1	CDK2	P24941	993
CCNB1	PLK1	P53350	982
CCNB1	CDC20	Q12834	970
CCNB1	BUB1B	O60566	967
CCNB1	CDC25C	P30307	951
CCNB1	H2AX	P16104	950
CCNB1	WEE1	P30291	932
CCNB1	TOP2A	P11388	926
CCNB1	CKS2	P33552	923
CCNB1	BCLAF1	Q9NYF8	912
CCNB1	TP53	P04637	909
CCNB1	PTCH1	Q13635	909
CCNB1	CCNL2	Q96S94	909
CCNB1	CKS1B	P33551	902

IntAct

173 interactions, top by confidence:

A	B	Type	Score
CCNB1	CDK1	psi-mi:“MI:0217”(phosphorylation reaction)	0.980
CCNB1	CDK1	psi-mi:“MI:0407”(direct interaction)	0.980
CDK1	CCNB1	psi-mi:“MI:0407”(direct interaction)	0.980
CDK1	CCNB1	psi-mi:“MI:0915”(physical association)	0.980
CCNB1	CDK1	psi-mi:“MI:0915”(physical association)	0.980
CCNB1	CDK1	psi-mi:“MI:0570”(protein cleavage)	0.980
CCNB1	CDK1	psi-mi:“MI:0914”(association)	0.980
CDK2	CCNE2	psi-mi:“MI:0914”(association)	0.940
CKS1B	CDK1	psi-mi:“MI:0914”(association)	0.920
ESPL1	PTTG1	psi-mi:“MI:0914”(association)	0.900
CDK2	CCNB1	psi-mi:“MI:0914”(association)	0.890
CDK5	CCNB1	psi-mi:“MI:0915”(physical association)	0.890
CDKN1A	CCNE2	psi-mi:“MI:0914”(association)	0.890
PKMYT1	CCNB1	psi-mi:“MI:0915”(physical association)	0.870
CCNB1	PKMYT1	psi-mi:“MI:0915”(physical association)	0.870
PKMYT1	CCNB1	psi-mi:“MI:2364”(proximity)	0.870
CCNB1	PKMYT1	psi-mi:“MI:2364”(proximity)	0.870
CDK2	CCNB2	psi-mi:“MI:0914”(association)	0.860

BioGRID (588): CCNB1 (Affinity Capture-Western), CCNB1 (Affinity Capture-Western), CCNB1 (Affinity Capture-MS), CCNB1 (Biochemical Activity), CCNB1 (Biochemical Activity), CCNB1 (Biochemical Activity), CCNB1 (Biochemical Activity), CCNB1 (Biochemical Activity), CCNB1 (Biochemical Activity), CCNB1 (Reconstituted Complex), CCNB1 (Biochemical Activity), CCNB1 (Reconstituted Complex), CCNB1 (Reconstituted Complex), CCNB1 (Reconstituted Complex), CCNB1 (Reconstituted Complex)

ESM2 similar proteins: F1N2W9, F1QDI9, F1QMB9, O77689, O93229, O95067, P07818, P13350, P13351, P13952, P14100, P14635, P15206, P24860, P24862, P29332, P30276, P30277, P37882, P37883, P54750, Q01061, Q01064, Q01065, Q01066, Q08301, Q08J23, Q0VGM9, Q1HFZ0, Q1LZG6, Q3TZI6, Q3ZBL9, Q4R7A8, Q60FX9, Q60FY0, Q61481, Q64395, Q6H1L8, Q8RWV3, Q92162

Diamond homologs: A0MEB5, A2YH60, O48790, O77689, O93229, O95067, P04962, P07818, P10815, P13350, P13351, P13952, P14635, P14785, P15206, P18606, P20248, P20439, P24860, P24861, P24862, P24871, P25010, P25011, P25012, P29332, P30183, P30274, P30276, P30277, P30278, P30284, P34800, P34801, P37881, P37882, P37883, P39963, P42524, P43449

SIGNOR signaling

21 interactions.

A	Effect	B	Mechanism
PLK1	“up-regulates activity”	CCNB1	phosphorylation
CDKN1A	down-regulates	CCNB1	binding
4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide	down-regulates	CCNB1	“chemical inhibition”
4-[[5-amino-1-[(2,6-difluorophenyl)-oxomethyl]-1,2,4-triazol-3-yl]amino]benzenesulfonamide	down-regulates	CCNB1	“chemical inhibition”
PTCH1	up-regulates	CCNB1	binding
CCNB1	“form complex”	CyclinB/CDK1	binding
R547	down-regulates	CCNB1	“chemical inhibition”
seliciclib	down-regulates	CCNB1	“chemical inhibition”
HLX	“up-regulates quantity by expression”	CCNB1	“transcriptional regulation”
RPRD1B	“up-regulates quantity by expression”	CCNB1	“transcriptional regulation”
MXI1	“down-regulates quantity by repression”	CCNB1	“transcriptional regulation”
CDC20	“down-regulates quantity by destabilization”	CCNB1	binding
CDC25C	“up-regulates activity”	CCNB1	dephosphorylation
CDC25A	“up-regulates activity”	CCNB1	dephosphorylation
AURKA	“up-regulates activity”	CCNB1	phosphorylation
NFY	“up-regulates quantity by expression”	CCNB1	“transcriptional regulation”
APC-c	“down-regulates quantity by destabilization”	CCNB1	ubiquitination
RFPL4A	“down-regulates quantity by destabilization”	CCNB1	ubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 130 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
G1/S DNA Damage Checkpoints	8	60.4×	3e-11
p53-Dependent G1 DNA Damage Response	7	56.1×	1e-09
p53-Dependent G1/S DNA damage checkpoint	7	56.1×	1e-09
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	6	48.1×	6e-08
TP53 Regulates Transcription of Cell Cycle Genes	7	42.8×	9e-09
G1 Phase	9	39.8×	6e-11
Cyclin A/B1/B2 associated events during G2/M transition	11	38.1×	5e-13
Cyclin A:Cdk2-associated events at S phase entry	12	35.8×	1e-13

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of DNA replication	6	30.1×	9e-06
G2/M transition of mitotic cell cycle	9	24.2×	3e-08
regulation of mitotic cell cycle	10	20.8×	2e-08
mitotic G2 DNA damage checkpoint signaling	5	19.1×	8e-04
G1/S transition of mitotic cell cycle	11	19.0×	7e-09
cell division	22	8.8×	6e-12
DNA repair	12	6.6×	5e-05
cilium assembly	9	5.7×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

66 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	50
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1301 predictions. Top by Δscore:

Variant	Effect	Δscore
5:69167074:G:GT	donor_gain	1.0000
5:69167282:GG:G	donor_gain	1.0000
5:69167283:GG:G	donor_gain	1.0000
5:69167904:TCAGA:T	acceptor_loss	1.0000
5:69167905:CAG:C	acceptor_loss	1.0000
5:69167906:A:AG	acceptor_gain	1.0000
5:69167906:AGA:A	acceptor_loss	1.0000
5:69167907:G:GG	acceptor_gain	1.0000
5:69167907:GA:G	acceptor_gain	1.0000
5:69168075:GAAG:G	donor_gain	1.0000
5:69168075:GAAGG:G	donor_loss	1.0000
5:69168076:AAGG:A	donor_loss	1.0000
5:69168078:GGTAA:G	donor_loss	1.0000
5:69168079:G:T	donor_loss	1.0000
5:69168080:T:G	donor_loss	1.0000
5:69168167:CTACA:C	acceptor_loss	1.0000
5:69168168:TACA:T	acceptor_loss	1.0000
5:69168170:CA:C	acceptor_loss	1.0000
5:69168171:A:AG	acceptor_gain	1.0000
5:69168172:G:GG	acceptor_gain	1.0000
5:69168172:GGAA:G	acceptor_gain	1.0000
5:69168314:G:GT	donor_gain	1.0000
5:69168340:TTTG:T	donor_loss	1.0000
5:69168343:GGTAA:G	donor_loss	1.0000
5:69168344:G:GG	donor_gain	1.0000
5:69168344:GT:G	donor_loss	1.0000
5:69168345:T:A	donor_loss	1.0000
5:69171265:TCAA:T	acceptor_loss	1.0000
5:69171266:CAAG:C	acceptor_loss	1.0000
5:69171267:A:AG	acceptor_gain	1.0000

AlphaMissense

2841 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:69174318:T:C	L205P	1.000
5:69174326:T:A	W208R	1.000
5:69174326:T:C	W208R	1.000
5:69174327:G:C	W208S	1.000
5:69174328:G:C	W208C	1.000
5:69174328:G:T	W208C	1.000
5:69174330:T:C	L209P	1.000
5:69174350:T:C	F216L	1.000
5:69174352:C:A	F216L	1.000
5:69174352:C:G	F216L	1.000
5:69174913:G:C	G248R	1.000
5:69174914:G:A	G248D	1.000
5:69174922:G:C	A251P	1.000
5:69174923:C:A	A251D	1.000
5:69174935:C:A	A255E	1.000
5:69174937:A:C	S256R	1.000
5:69174939:C:A	S256R	1.000
5:69174939:C:G	S256R	1.000
5:69174941:A:T	K257I	1.000
5:69174942:A:C	K257N	1.000
5:69174942:A:T	K257N	1.000
5:69175028:A:T	E286V	1.000
5:69175084:T:C	F305L	1.000
5:69175086:C:A	F305L	1.000
5:69175086:C:G	F305L	1.000
5:69175095:A:C	R308S	1.000
5:69175095:A:T	R308S	1.000
5:69171439:T:C	L178P	0.999
5:69174307:G:A	M201I	0.999
5:69174307:G:C	M201I	0.999

dbSNP variants (sampled 300 via entrez): RS1000074608 (5:69177084 C>G), RS1000384479 (5:69166395 A>C,G), RS1000415781 (5:69166739 G>A,C,T), RS1000445690 (5:69169396 T>C), RS1000478296 (5:69169082 A>T), RS1000716331 (5:69174129 A>G,T), RS1000750363 (5:69167878 C>G,T), RS1000780793 (5:69175608 T>C), RS1001265980 (5:69166850 G>A), RS1001305163 (5:69166994 G>A,T), RS1001319017 (5:69177970 T>C), RS1001461992 (5:69172381 C>T), RS1001511565 (5:69176259 A>G), RS1001616563 (5:69169978 T>C), RS1001647904 (5:69172598 T>A,C)

Disease associations

OMIM: gene MIM:123836 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (5): CHEMBL1907602 (PROTEIN COMPLEX), CHEMBL2094127 (PROTEIN COMPLEX GROUP), CHEMBL2412 (SINGLE PROTEIN), CHEMBL4523630 (PROTEIN COMPLEX), CHEMBL4680053 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

34 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 145,768 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL189963	PALBOCICLIB	4	13,102
CHEMBL3301610	ABEMACICLIB	4	7,045
CHEMBL1096380	PLINABULIN	3	686
CHEMBL2103840	DINACICLIB	3	2,257
CHEMBL407874	6-O-BENZYLGUANINE	3	6,988
CHEMBL428690	ALVOCIDIB	3	27,781
CHEMBL50	QUERCETIN	3	74,559
CHEMBL1230165	SILMITASERTIB	2	593
CHEMBL1276127	INDIRUBIN	2	181
CHEMBL14762	SELICICLIB	2	3,787
CHEMBL1944698	ZOTIRACICLIB	2	2,915
CHEMBL2347597	ASNUCICLIB	2	100
CHEMBL3115681	NARAZACICLIB	2	287
CHEMBL3655762	CYC-065	2	388
CHEMBL3905910	VORUCICLIB	2	856
CHEMBL4442620	RONICICLIB	2	367
CHEMBL445813	AT-7519	2	2,614
CHEMBL4462530	ZEMIRCICLIB	2	429
CHEMBL5095094	CULMERCICLIB	2	12
CHEMBL564829	MILCICLIB	2	821
CHEMBL8260	BAICALEIN	2
CHEMBL151	LUTEOLIN	2
CHEMBL31574	FISETIN	2
CHEMBL3545283	RIVICICLIB	2
CHEMBL1230607	PHA-793887	1
CHEMBL258805	SU-9516	1
CHEMBL296468	BMS-387032	1
CHEMBL3545083	RGB-286638	1
CHEMBL4169078	SRA-737	1
CHEMBL4439321	ATUVECICLIB	1

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

379 measured of 508 human assays (523 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
4-{[3-(4-aminophenyl)-1H-pyrazol-5-yl]amino}benzene-1-sulfonamide	IC50	0.34 nM
(12Z)-12-{[(4-{[2-(2-hydroxyethoxy)ethyl]sulfamoyl}phenyl)amino]methylidene}-3-thia-5,10-diazatricyclo[7.3.0.0^{2,6}]dodeca-1,4,6,8-tetraen-11-one	IC50	0.54 nM
5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-N-(pyrimidin-4-yl)-1,3-thiazol-2-amine	IC50	1 nM
N-methyl-4-({[(12Z)-11-oxo-3-thia-5,10-diazatricyclo[7.3.0.0^{2,6}]dodeca-1,4,6,8-tetraen-12-ylidene]methyl}amino)-N-(2,5,8,11-tetraoxatridecan-13-yl)benzene-1-sulfonamide	IC50	1 nM
4-{2-[(3Z)-4-(2-methylpropyl)-2-oxo-2,3-dihydro-1H-indol-3-ylidene]hydrazin-1-yl}benzene-1-sulfonamide	IC50	1.2 nM
1-(2,6-difluorophenyl)-3-{3-[5-(morpholin-4-ylmethyl)-1H-1,3-benzodiazol-2-yl]-1H-pyrazol-4-yl}urea	IC50	1.5 nM
4-{2-[(3Z)-4-(2-methylprop-1-en-1-yl)-2-oxo-2,3-dihydro-1H-indol-3-ylidene]hydrazin-1-yl}benzene-1-sulfonamide	IC50	1.5 nM
4-({[(3Z)-4-oxo-5,10-diazatricyclo[7.4.0.0^{2,6}]trideca-1,6,8,10,12-pentaen-3-ylidene]methyl}amino)benzene-1-sulfonamide	IC50	1.5 nM
4-[N -2-Oxo-2,3-dihydropyrrolo[3,2-f]quinolin-1-ylidene)-hydrazino]benzenesulfonamide	IC50	1.6 nM
3-{[4-(Aminosulfonyl)phenyl]hydrazono}-N-(2,6-dimethoxybenzyl)-2-oxo-5-indolinecarboxamide	IC50	1.7 nM
4-({[(3Z)-5-(3-methylbutanoyl)-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}amino)benzene-1-sulfonamide	IC50	1.9 nM
2-N-(1-methanesulfonylpiperidin-4-yl)-5-[(2,3,4-trifluoro-6-methoxyphenyl)carbonyl]pyrimidine-2,4-diamine	KI	2 nM
N-(2,6-Difluorophenyl)-N-[5-[[[5-tert-butyl-2-oxazolyl]-methyl]thio]-2-thiazolyl]urea	IC50	2 nM
5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-N-(pyridin-2-yl)-1,3-thiazol-2-amine	IC50	2 nM
N-{4-[(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)amino]phenyl}-2-hydroxyethane-1-sulfonamido	IC50	2 nM
4-[1-(5-Oxazol-5-yl-2-oxo-1,2-dihydro-indol-3-ylidene)-ethylamino]benzenesulfonamide	IC50	2 nM
4-[[5-Amino-1-[(3-fluoro-2-thienyl)carbonyl]-1H-1,2,4-triazol-3-yl]amino]-benzenesulfonamide	IC50	2.1 nM
methyl (3Z)-2-oxo-3-{[(4-sulfamoylphenyl)amino]methylidene}-2,3-dihydro-1H-indole-5-carboxylate	IC50	2.1 nM
3-{[4-(Aminosulfonyl)phenyl]hydrazono}-2-oxo-N-(3-pyridinylmethyl)-2,3-dihydro-1H-indole-5-carboxamide	IC50	2.1 nM
4-[N -(1-Chloro-7-oxo-6,7-dihydro-3H-pyrrolo[3,2-e]indazol-8-ylidene)-hydrazino]benzenesulfonamide	IC50	2.2 nM
4-{2-[(3Z)-5-(1,3-oxazol-5-yl)-2-oxo-2,3-dihydro-1H-indol-3-ylidene]hydrazin-1-yl}benzene-1-sulfonamide	IC50	2.3 nM
4-({[(3Z)-5-(1,3-oxazol-5-yl)-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}amino)benzene-1-sulfonamide	IC50	2.5 nM
4-[N’-(4-Isopropyl-2-oxo-1,2-dihydro-indol-3-ylidene)-hydrazino]benzenesulfonamide	IC50	2.5 nM
1-(2-fluorophenyl)-3-{3-[5-(morpholin-4-ylmethyl)-1H-1,3-benzodiazol-2-yl]-1H-pyrazol-4-yl}urea	IC50	2.8 nM
4-({[(12Z)-11-oxo-3-thia-5,10-diazatricyclo[7.3.0.0^{2,6}]dodeca-1,4,6,8-tetraen-12-ylidene]methyl}amino)benzene-1-sulfonamide	IC50	2.8 nM
2,4-Diamino-5-ketopyrimidine 39	KI	3 nM
4-N-(2,6-difluorobenzene)-3-N-(4-fluorophenyl)-1H-pyrazole-3,4-diamido	IC50	3 nM
3-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)-1-(2,6-dichlorophenyl)urea	IC50	3 nM
N-[5-[[[5-tert-Butyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-[[[bis(hydroxymethyl)methyl]amino]methyl]benzeneacetamide Hydrochloride Salt	IC50	3 nM
5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-N-(pyridin-3-yl)-1,3-thiazol-2-amine	IC50	3 nM
3-[({6-[(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)amino]pyridin-3-yl}methyl)amino]-2,2-dimethylpropan-1-ol	IC50	3 nM
Isobutyl 3-{[4-(aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1H-indole-5-carboxylate	IC50	3 nM
4-[[5-Amino-1-(2,3,6-trifluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]-benzenesulfonamide	IC50	3.2 nM
4-({5-amino-1-[(3,5-dimethylthiophen-2-yl)carbonyl]-1H-1,2,4-triazol-3-yl}amino)benzene-1-sulfonamide	IC50	3.2 nM
3-amino-N-(2,6-difluorophenyl)-5-[(4-sulfamoylphenyl)amino]-1H-1,2,4-triazole-1-carbothioamide	IC50	3.2 nM
8-{[4-({[Amino(imino)methyl]amino}sulfonyl)anilino]-methylene}-7-oxo-7,8-dihydro-6H-[1,3]thiazolo[5,4-e]indole	IC50	3.3 nM
4-{2-[(3Z)-2-oxo-4-(propan-2-yloxy)-2,3-dihydro-1H-indol-3-ylidene]hydrazin-1-yl}benzene-1-sulfonamide	IC50	3.4 nM
N-{3-[5-(morpholin-4-ylmethyl)-1H-1,3-benzodiazol-2-yl]-1H-pyrazol-4-yl}benzamide	IC50	3.5 nM
N-[2-(1H-imidazol-5-yl)ethyl]-4-({[(12Z)-11-oxo-3-thia-5,10-diazatricyclo[7.3.0.0^{2,6}]dodeca-1,4,6,8-tetraen-12-ylidene]methyl}amino)benzene-1-sulfonamide	IC50	3.6 nM
5-Amino-3-[[4-(aminosulfonyl)phenyl]amino]-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carboamide	IC50	3.7 nM
N-[5-[[[5-(Cyclohexylmethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]acetamide	IC50	4 nM
5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-N-phenyl-1,3-thiazol-2-amine	IC50	4 nM
Pyrazolopyrimidone analog, RGB-286331	IC50	4 nM
4-({[(12Z)-11-oxo-3-thia-5,10-diazatricyclo[7.3.0.0^{2,6}]dodeca-1,4,6,8-tetraen-12-ylidene]methyl}amino)-N-phenylbenzene-1-sulfonamide	IC50	4.3 nM
4-[[5-Amino-1-(2-thienylcarbonyl)-1H-1,2,4-triazol-3-yl]amino]-benzenesulfonamide	IC50	4.5 nM
(3Z)-2-oxo-3-[2-(4-sulfamoylphenyl)hydrazin-1-ylidene]-2,3-dihydro-1H-indole-5-carboxamide	IC50	4.5 nM
4-({[(12Z)-11-oxo-3-thia-5,10-diazatricyclo[7.3.0.0^{2,6}]dodeca-1,4,6,8-tetraen-12-ylidene]methyl}amino)-N-(2,5,8,11-tetraoxatridecan-13-yl)benzene-1-sulfonamide	IC50	4.5 nM
4-[N’-(4-Iodo-2-oxo-1,2-dihydro-indol-3-ylidene)-hydrazino]benzenesulfonamide	IC50	4.6 nM
4-{2-[(3Z)-4-methyl-5-nitro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]hydrazin-1-yl}benzene-1-sulfonamide	IC50	4.6 nM
N,N-dimethyl-4-({[(12Z)-11-oxo-3-thia-5,10-diazatricyclo[7.3.0.0^{2,6}]dodeca-1,4,6,8-tetraen-12-ylidene]methyl}amino)benzene-1-sulfonamide	IC50	4.6 nM

ChEMBL bioactivities

1204 potent at pChembl≥5 of 1487 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.30	Ki	0.5	nM	CHEMBL2348843
9.22	IC50	0.6	nM	CHEMBL261720
9.22	IC50	0.6	nM	CHEMBL384350
9.22	IC50	0.6	nM	CHEMBL426509
9.15	IC50	0.7	nM	CHEMBL511394
9.00	Ki	1	nM	CHEMBL2348844
9.00	IC50	1	nM	CHEMBL3897452
9.00	IC50	1	nM	CHEMBL212552
8.89	IC50	1.3	nM	STAUROSPORINE
8.86	IC50	1.38	nM	STAUROSPORINE
8.85	IC50	1.42	nM	STAUROSPORINE
8.85	IC50	1.4	nM	XYLOCYDINE
8.82	Ki	1.5	nM	CHEMBL2348842
8.80	IC50	1.6	nM	STAUROSPORINE
8.79	IC50	1.63	nM	STAUROSPORINE
8.74	IC50	1.8	nM	CHEMBL3716786
8.72	IC50	1.9	nM	CHEMBL377449
8.71	IC50	1.97	nM	STAUROSPORINE
8.70	Ki	2	nM	CHEMBL2348847
8.70	IC50	2	nM	RGB-286638
8.70	IC50	2	nM	CHEMBL212299
8.70	IC50	2	nM	CHEMBL261720
8.70	IC50	2	nM	CHEMBL4748292
8.68	IC50	2.1	nM	CHEMBL361900
8.67	IC50	2.16	nM	STAUROSPORINE
8.64	IC50	2.3	nM	CHEMBL4589128
8.62	IC50	2.4	nM	STAUROSPORINE
8.60	IC50	2.52	nM	STAUROSPORINE
8.52	IC50	3	nM	CHEMBL363607
8.52	IC50	3	nM	CHEMBL3604469
8.52	IC50	3	nM	DINACICLIB
8.52	IC50	3	nM	CHEMBL212491
8.52	Ki	3	nM	DINACICLIB
8.52	IC50	3	nM	CHEMBL1825101
8.49	IC50	3.2	nM	CHEMBL425720
8.49	IC50	3.2	nM	CHEMBL187395
8.49	IC50	3.2	nM	CHEMBL364927
8.49	IC50	3.2	nM	STAUROSPORINE
8.49	IC50	3.2	nM	CHEMBL1684800
8.48	IC50	3.3	nM	STAUROSPORINE
8.43	IC50	3.7	nM	CHEMBL370698
8.40	Ki	4	nM	CHEMBL2348845
8.40	Ki	4	nM	ASNUCICLIB
8.40	IC50	4	nM	CHEMBL3604462
8.40	IC50	4	nM	CHEMBL3604468
8.40	IC50	4	nM	PURVALANOLA
8.40	IC50	4	nM	CHEMBL430653
8.40	IC50	4	nM	CHEMBL1825100
8.35	IC50	4.5	nM	CHEMBL190643
8.32	IC50	4.8	nM	CHEMBL363130

PubChem BioAssay actives

1524 with measured affinity, of 3345 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-[[4-[2-(methylamino)-4-(trifluoromethyl)-1,3-thiazol-5-yl]pyrimidin-2-yl]amino]benzenesulfonamide	741494: Inhibition of human recombinant His6 tagged CDK1/Cyclin B expressed in Sf21 insect cells after 40 mins by scintillation counting analysis	ki	0.0005	uM
N-[2-methyl-4-(2-pyrrolidin-1-ylethyl)phenyl]-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine	270821: Inhibition of CDK1/cyclinB by Flashplate assay	ic50	0.0006	uM
2-[3-methyl-4-[[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]ethanol	270821: Inhibition of CDK1/cyclinB by Flashplate assay	ic50	0.0006	uM
5-amino-N-(2,6-difluorophenyl)-3-(4-sulfamoylanilino)-1,2,4-triazole-1-carbothioamide	1795974: Kinase Inhibition Assay from Article 10.1021/jm050267e: “1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.”	ic50	0.0006	uM
N-[[5-[3-(6-fluoro-1H-benzimidazol-2-yl)-3H-pyrazolo[3,4-b]pyridin-5-yl]-3-pyridinyl]methyl]ethanamine	365550: Inhibition of CDK1/cyclinB	ic50	0.0007	uM
N-[[5-[3-(4,6-difluoro-1H-benzimidazol-2-yl)-1H-indazol-4-yl]-4-methyl-3-pyridinyl]methyl]ethanamine	1317305: Inhibition of CDK1/cyclin B (unknown origin)	ic50	0.0010	uM
N-[2-methyl-4-(2-piperidin-1-ylethyl)phenyl]-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine	270821: Inhibition of CDK1/cyclinB by Flashplate assay	ic50	0.0010	uM
(3Z)-5-(2-chloroacetyl)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one	606558: Inhibition of human Cdk1/cyclinB using histone H1 as a substrate and [gamma-32P]ATP	ic50	0.0010	uM
(3Z)-5-(2-chloroacetyl)-3-[(5-methyl-1H-imidazol-4-yl)methylidene]-1H-indol-2-one	606558: Inhibition of human Cdk1/cyclinB using histone H1 as a substrate and [gamma-32P]ATP	ic50	0.0010	uM
N-[(3Z)-3-(1H-imidazol-5-ylmethylidene)-2-oxo-1H-indol-5-yl]prop-2-ynamide	606558: Inhibition of human Cdk1/cyclinB using histone H1 as a substrate and [gamma-32P]ATP	ic50	0.0010	uM
N-[(3Z)-3-[(5-methyl-1H-imidazol-4-yl)methylidene]-2-oxo-1H-indol-5-yl]prop-2-ynamide	606558: Inhibition of human Cdk1/cyclinB using histone H1 as a substrate and [gamma-32P]ATP	ic50	0.0010	uM
[4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone	1796919: Homogeneous Time-resolved Fluorescence (HTRF) Assay from Article 10.1021/jm0606138: “Discovery of 4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-ylmethanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.”	ki	0.0010	uM
4-[[4-[2-(methylamino)-1,3-thiazol-5-yl]pyrimidin-2-yl]amino]benzenesulfonamide	741494: Inhibition of human recombinant His6 tagged CDK1/Cyclin B expressed in Sf21 insect cells after 40 mins by scintillation counting analysis	ki	0.0010	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	629267: Inhibition of CDK1/Cyclin B	ic50	0.0013	uM
4-amino-6-bromo-7-[(2S,3S,4S,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carboxamide	632963: Inhibition of CDK1/Cyclin B in human HeLa cell extracts using histone H1 as substrate preincubated for 30 mins before substrate addition measured after 15 mins by autoradiography	ic50	0.0014	uM
3-[[4-[2-(methylamino)-4-(trifluoromethyl)-1,3-thiazol-5-yl]pyrimidin-2-yl]amino]benzenesulfonamide	741494: Inhibition of human recombinant His6 tagged CDK1/Cyclin B expressed in Sf21 insect cells after 40 mins by scintillation counting analysis	ki	0.0015	uM
N-[2-methyl-4-(2-morpholin-4-ylethyl)phenyl]-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine	270821: Inhibition of CDK1/cyclinB by Flashplate assay	ic50	0.0019	uM
1-[3-[4-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]phenyl]-4-oxo-1H-indeno[2,1-d]pyrazol-5-yl]-3-morpholin-4-ylurea	1317305: Inhibition of CDK1/cyclin B (unknown origin)	ic50	0.0020	uM
(2R,3R)-3-[5-bromo-2-[4-(ethylsulfonimidoyl)anilino]pyrimidin-4-yl]oxybutan-2-ol	1704619: Inhibition of GST-tagged recombinant human CDK1/GST-tagged human cyclin B expressed in Sf-9 cells incubated for 10 mins by scintillation counting method	ic50	0.0020	uM
4-N-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]cyclohexane-1,4-diamine	270821: Inhibition of CDK1/cyclinB by Flashplate assay	ic50	0.0020	uM
4-[[4-[4-cyclopropyl-2-(methylamino)-1,3-thiazol-5-yl]pyrimidin-2-yl]amino]benzenesulfonamide	741494: Inhibition of human recombinant His6 tagged CDK1/Cyclin B expressed in Sf21 insect cells after 40 mins by scintillation counting analysis	ki	0.0020	uM
4-[[5-amino-1-(3-fluorothiophene-2-carbonyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	1795974: Kinase Inhibition Assay from Article 10.1021/jm050267e: “1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.”	ic50	0.0021	uM
N-[[5-[3-(4,6-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-3-pyridinyl]methyl]ethanamine	1549287: Inhibition of CDK1/Cyclin B (unknown origin) using histone H1 as substrate in presence of gamma[32P] ATP by phosphorimaging analysis	ic50	0.0023	uM
2-hydroxy-3-[(4-sulfamoylphenyl)diazenyl]-1H-indole-5-carboxamide	1796078: Kinase Inhibition SPA Assay from Article 10.1021/jm010117d: “Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.”	ic50	0.0028	uM
4-[[1-(2,6-difluoro-3-methylbenzoyl)-5-methyl-1,2,4-triazol-3-yl]amino]benzenesulfonamide	241014: Inhibition of Cyclin B-cyclin-dependent kinase 1	ic50	0.0030	uM
N-(2-methylphenyl)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine	270821: Inhibition of CDK1/cyclinB by Flashplate assay	ic50	0.0030	uM
2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol	1317325: Inhibition of recombinant CDK1/cyclin B (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotinylated histone H1 as substrate after 1 hr by gamma32P-ATP based liquid scintillation counting analysis	ic50	0.0030	uM
N-(2-aminoethyl)-N-[5-[(1-cycloheptylpyrazolo[3,4-d]pyrimidin-6-yl)amino]-2-pyridinyl]methanesulfonamide	617336: Inhibition of CDK1/Cyclin B assessed as phosphorylation of Z-lyte Peptide at 0.017 to 30 nM by FRET assay	ic50	0.0030	uM
(2R,3R)-3-[[5-bromo-2-[4-(ethylsulfonimidoyl)anilino]pyrimidin-4-yl]amino]butan-2-ol	1239767: Inhibition of recombinant CDK1/GST-fused cyclin B (unknown origin) expressed in baculovirus infected insect Sf9 cells by substrate phosphorylation assay in presence of [33P]-gamma adenosine triphosphate	ic50	0.0030	uM
4-[[5-methyl-1-(2,3,6-trifluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	241014: Inhibition of Cyclin B-cyclin-dependent kinase 1	ic50	0.0032	uM
4-[[5-amino-2-(2,6-difluorobenzenecarbothioyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	241014: Inhibition of Cyclin B-cyclin-dependent kinase 1	ic50	0.0032	uM
N-[5-amino-1-[(4-methoxyphenyl)methyl]pyrazol-4-yl]-5-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-2-methylbenzamide	578724: Inhibition of CDK1/cyclin B	ic50	0.0032	uM
4-[[5-amino-1-(2,3,6-trifluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	1795974: Kinase Inhibition Assay from Article 10.1021/jm050267e: “1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.”	ic50	0.0032	uM
4-[[5-amino-1-(3,5-dimethylthiophene-2-carbonyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	1795974: Kinase Inhibition Assay from Article 10.1021/jm050267e: “1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.”	ic50	0.0032	uM
3-amino-N-(2,6-difluorophenyl)-5-(4-sulfamoylanilino)-1,2,4-triazole-1-carbothioamide	1795974: Kinase Inhibition Assay from Article 10.1021/jm050267e: “1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.”	ic50	0.0032	uM
5-amino-N-(2,6-difluorophenyl)-3-(4-sulfamoylanilino)-1,2,4-triazole-1-carboxamide	1795974: Kinase Inhibition Assay from Article 10.1021/jm050267e: “1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.”	ic50	0.0037	uM
N-(4-methoxyphenyl)-4-(2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine	1239760: Inhibition of human CDK1/cyclin B1 (unknown origin)	ic50	0.0040	uM
4-[[5-bromo-4-[(2R,3R)-3-hydroxybutan-2-yl]oxypyrimidin-2-yl]amino]benzenesulfinamide	1239767: Inhibition of recombinant CDK1/GST-fused cyclin B (unknown origin) expressed in baculovirus infected insect Sf9 cells by substrate phosphorylation assay in presence of [33P]-gamma adenosine triphosphate	ic50	0.0040	uM
(2R)-2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol	1798788: CDK Inhibition Assay from Article 10.1021/jm801340z: “Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue.”	ic50	0.0040	uM
5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-N-pyridin-2-yl-1,3-thiazol-2-amine	1795808: Kinase Inhibition assay from Article 10.1016/j.bmcl.2004.02.105: “Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.”	ic50	0.0040	uM
N-[5-[(1-cycloheptylpyrazolo[3,4-d]pyrimidin-6-yl)amino]-2-pyridinyl]-N-(2-hydroxyethyl)methanesulfonamide	617336: Inhibition of CDK1/Cyclin B assessed as phosphorylation of Z-lyte Peptide at 0.017 to 30 nM by FRET assay	ic50	0.0040	uM
3-[[5-fluoro-4-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]pyrimidin-2-yl]amino]benzenesulfonamide	1940563: Inhibition of CDK1/Cyclin B (unknown origin) assessed as inhibition constant	ki	0.0040	uM
3-[[4-[2-(methylamino)-1,3-thiazol-5-yl]pyrimidin-2-yl]amino]benzenesulfonamide	741494: Inhibition of human recombinant His6 tagged CDK1/Cyclin B expressed in Sf21 insect cells after 40 mins by scintillation counting analysis	ki	0.0040	uM
4-[[5-amino-1-(thiophene-2-carbonyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	1795974: Kinase Inhibition Assay from Article 10.1021/jm050267e: “1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.”	ic50	0.0045	uM
4-[[5-amino-1-(3-methylthiophene-2-carbonyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	1795974: Kinase Inhibition Assay from Article 10.1021/jm050267e: “1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.”	ic50	0.0048	uM
4-(4-methylpiperazin-1-yl)-N-[4-(2-methyl-3-propan-2-ylindazol-5-yl)pyrimidin-2-yl]quinolin-7-amine	1771101: Inhibition of human CDK1/cyclinB using Histone H1 as substrate incubated for 2 hrs by [gamma-33P]-ATP assay	ic50	0.0049	uM
[4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3,4-trifluoro-6-methoxyphenyl)methanone	1796919: Homogeneous Time-resolved Fluorescence (HTRF) Assay from Article 10.1021/jm0606138: “Discovery of 4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-ylmethanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.”	ki	0.0050	uM
4-[[5-chloro-4-(1-methylpyrazol-4-yl)pyrimidin-2-yl]amino]benzenesulfonamide	1940568: Inhibition of CDK1/Cyclin B (unknown origin) assessed as inhibition constant incubated for 30 to 60 mins presence of dithiothreitol by Cheng-Prusoff equation analysis	ki	0.0050	uM
3-[[5-fluoro-4-(1-methylpyrazol-4-yl)pyrimidin-2-yl]amino]benzenesulfonamide	1940568: Inhibition of CDK1/Cyclin B (unknown origin) assessed as inhibition constant incubated for 30 to 60 mins presence of dithiothreitol by Cheng-Prusoff equation analysis	ki	0.0050	uM
3-[[5-chloro-4-(1-methylpyrazol-4-yl)pyrimidin-2-yl]amino]benzenesulfonamide	1940568: Inhibition of CDK1/Cyclin B (unknown origin) assessed as inhibition constant incubated for 30 to 60 mins presence of dithiothreitol by Cheng-Prusoff equation analysis	ki	0.0050	uM

CTD chemical–gene interactions

422 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Resveratrol	affects expression, affects binding, decreases activity, decreases expression, affects cotreatment (+2 more)	12
sodium arsenite	decreases degradation, increases stability, affects reaction, decreases reaction, decreases expression (+2 more)	11
Doxorubicin	affects response to substance, affects expression, increases reaction, decreases reaction, affects cotreatment (+3 more)	11
Paclitaxel	increases reaction, decreases reaction, increases response to substance, affects reaction, increases activity (+5 more)	11
bisphenol A	decreases expression, affects cotreatment, decreases reaction, increases expression, affects expression	10
Quercetin	affects cotreatment, increases expression, affects binding, decreases reaction, decreases expression	10
Arsenic Trioxide	decreases reaction, affects cotreatment, increases expression, decreases expression	9
Cisplatin	affects binding, decreases reaction, increases expression, affects cotreatment, decreases expression (+1 more)	7
Estradiol	affects expression, affects cotreatment, increases expression, decreases expression, decreases reaction	6
ochratoxin A	affects reaction, affects binding, decreases reaction, decreases expression, affects cotreatment (+1 more)	5
diallyl trisulfide	decreases activity, decreases expression, increases expression, affects localization, affects binding (+1 more)	5
alvocidib	affects cotreatment, decreases expression, decreases reaction, increases expression, decreases activity	5
Benzo(a)pyrene	decreases expression, increases degradation, increases expression	5
Cadmium	increases abundance, increases expression, decreases expression, affects reaction	5
Camptothecin	affects cotreatment, decreases expression, increases expression, affects reaction	5
Fluorouracil	decreases expression, increases reaction, affects reaction, decreases reaction	5
Troglitazone	decreases expression, decreases reaction, affects response to substance, decreases activity, increases response to substance	4
trichostatin A	decreases expression	3
perfluorooctanoic acid	affects expression, decreases expression, increases expression	3
ON 01910	decreases expression, increases expression	3
2,2’,4,4’-tetrabromodiphenyl ether	affects expression, affects cotreatment, increases expression	3
(+)-JQ1 compound	affects cotreatment, decreases expression	3
Bortezomib	increases expression, increases ubiquitination, increases response to substance	3
Acrolein	increases oxidation, decreases expression, increases abundance, affects localization, affects response to substance (+1 more)	3
Air Pollutants	increases abundance, increases oxidation, decreases expression, affects cotreatment	3
Curcumin	decreases expression	3
Oxygen	affects cotreatment, decreases expression, increases reaction, affects expression, affects reaction (+1 more)	3
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	3
Cyclosporine	decreases expression	3
Cadmium Chloride	affects cotreatment, decreases reaction, increases expression, decreases expression, increases abundance (+1 more)	3

ChEMBL screening assays

631 unique, capped per target: 620 binding, 8 admet, 2 functional, 1 unclassified

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1000364	Binding	Inhibition of Cdc2/cyclin B assessed as inhibition of histone H1 phosphorylation in human HT29 cells	Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases. — Eur J Med Chem
CHEMBL4004950	ADMET	Inhibition of recombinant human CDK1/Cyclin B expressed in baculovirus infected Sf9 cells at using PKTPKKAKKL-NH2 as substrate relative to untreated control	Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. — J Med Chem
CHEMBL700201	Functional	In vitro antiproliferative activity against myeloid leukemia K562 cell line	Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors. — Bioorg Med Chem Lett

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B9ER	Abcam A-549 CCNB1 KO	Cancer cell line	Male
CVCL_SH30	HAP1 CCNB1 (-) 1	Cancer cell line	Male
CVCL_SH31	HAP1 CCNB1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.